---
title: Why brand teams miss commercial growth (and what the data reveals)
description: Discover how brand teams can uncover hidden growth opportunities by leveraging comprehensive healthcare data and refining targeting strategies for better patient engagement.
---

[HealthVerity Blog](https://blog.healthverity.com)

# [Why brand teams miss commercial growth (and what the data reveals)](https://blog.healthverity.com/why-brand-teams-miss-commercial-growth-and-what-the-data-reveals)

 Written by [HealthVerity](https://blog.healthverity.com/author/healthverity) | Nov 19, 2026, 9:00:00 AM

In atopic dermatitis, 23% of new patient starts come from HCPs that brand teams either deprioritize or don’t have in their data at all. One in three top-decile prescribers in that same market saw zero new patient starts over a 22-month stretch. In obesity, claim-based diagnosis alone misses nearly 30% of eligible patients.

These patterns show up whenever commercial teams work from volume-based targeting and single-source data alone. In our [recent webinar](https://info.healthverity.com/your-brands-next-growth-opportunity-is-hiding-in-plain-sight) on uncovering blind spots in your brand performance, David Menzies and Paul Cariola, leaders in our consulting and technology solutions practices, walked through where these blind spots can hide and how the combined [HealthVerity and Symphony Health](https://healthverity.com/symphony-health/) data ecosystem closes them.

<https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLL1jbA2GV3bCZVmm3JS0Fh1%2BhWipkW4iaPk2W8WRRzvhZ2McGV9%2B7oCJ4Ej7qFGwdgcr%2FbR8WWUQU0G75Qd1%2BXdmQv%2FJruY7Fp1EemxF4GUlieYkGuDXVdIzateHEDrDC01DuquHiOOzdEEGs4Pvca9eARPQ3Lrry%2BKdhN96BSskgqnCR%2FM6jI%2FM9o3xSf4SA%2BbhZiB3BSCNvgomy%2FvD3AFXmqoKY%2FW7x9W%2Bgqh9KTlS%2BHHhFGmTNxsQqkagFTk%2FNF0bIlP%2BoGXAoDOgbrQHBM%3D&webInteractiveContentId=227634226695&portalId=5412465>

## Know what others can’t: the growth hiding outside your target list

A quarter of new starts in some therapeutic areas come from HCPs that look low-priority on a volume-only ranking or don’t appear in a brand team’s data at all. Forecasts, incentive compensation plans and field deployments built on that view are missing a meaningful share of the opportunity.

Volume still matters for commercial targeting. It just no longer tells the whole story. When commercial leadership asks why a brand isn’t growing as forecasted, “we had the wrong data” is a hard answer to give.

## Fragmented data, fragmented view of the market

Healthcare data has historically split between aggregator-only and marketplace-only models. Teams subscribing to one approach have been missing patients and HCPs that the other captures, often without realizing the gap exists.

By combining HealthVerity and Symphony Health, we have resolved that tradeoff and unified clinical depth with commercial breadth into one longitudinal, de-duped, HIPAA-compliant view of patients and providers. A few examples of what surfaces when the comprehensive view is in place:

- **Lung cancer:** bringing together open and closed claims lifted the visible patient view by 59% and identified 15% more HCPs worth targeting\*

- **Obesity:** adding EMR data to claims revealed 28.8% more relevant patients\*\*

- **GLP-1 therapies:** consumer credit card data synced at the de-identified patient level captured 33% more patients on therapy, including those using direct-to-patient channels like Hims, Ro and LillyDirect\*\*\*

 

As David noted on the webinar, a comprehensive picture often comes from unexpected places. Distribution channels are shifting, and data strategy has to shift with them.

## From comprehensive data to precise action: the HCP readiness score

Two prescribers with identical market volume aren’t equivalent opportunities. Diagnostic activity, clinical characteristics, referral and influence patterns and adoption willingness all change how a prescriber should be prioritized. The HCP readiness score combines those signals to show where patient volume exists alongside the evidence that a prescriber is ready to adopt.

Paul walked through an atopic dermatitis engagement where a client with limited field presence needed to do more with less. By applying the readiness score across the expanded data, we grew the target list by 33%, aligned it to the client’s geographies and captured more than 90% of new starts over the following six months with only 500 additional doctors.

## Pressure-testing trigger and alert programs

Market dynamics change constantly, and prior education reshapes HCP behavior. A trigger that drove business 12 months ago may just be generating noise today. Two examples stand out from the webinar:

### Advanced oncology:

Two signals drove nearly 90% of patient acquisition tied to disease progression. Four signals that had worked historically weren’t predictive anymore, so we deprioritized them

### MASH:

A diagnostic review cut alert volume by 67% while preserving 85% of expected conversions

[eXOs](https://healthverity.com/exos/) supports this kind of evaluation in hours or days rather than weeks and months. There’s no reason to wait a full quarter to pressure-test a program that may already be out of date.

## Questions worth asking about your own commercial strategy

If your target lists, triggers and launch plans were built on single-source data alone, they’re almost certainly leaving growth on the table. A few diagnostic questions:

- Are the HCPs driving new starts in your market actually on your target list?
- Are your triggers still predictive, or has the signal gone stale?
- Can you route the right message, through the right channel, in time to act?

Your next growth opportunity may be hiding beyond your current target list, in patient populations your data doesn't capture or in signals your strategy has yet to consider. Knowing where to look, and having the right data to act, can make the difference between measuring brand performance and driving it.

[Watch the full webinar on demand](https://info.healthverity.com/your-brands-next-growth-opportunity-is-hiding-in-plain-sight) to see the case studies in detail, or talk with our team to scope a diagnostic on your own commercial data.

<https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLK0PsQ33gzfg5nMltjsfMTn6W9A5jAcord60IRqcKXQ%2BuCGYD3JjBDUhbn41ZiI%2Bbogl0N8yokfiGArvqZLaJjKr24K%2F6OCkKU2UqqjfZG7vH2mZ0eXEx3TDuqUkqd1A4aYKtHJ&webInteractiveContentId=227641560122&portalId=5412465>

 

*\* Source: HealthVerity analysis for a lung cancer brand (blinded); patients with a primary lung cancer diagnosis treated with market therapies, Jul 2023–Jun 2025; baseline open claims, plus additional HealthVerity open medical and pharmacy sources, plus closed claims, deduplicated. Compared with the brand's existing HCP list; some tier differences reflect targeting rules (exclusions, NP/PA handling). List comparison, not an outcome back-test. Uplift may vary by specific use case.*

*\*\* Source: HealthVerity analysis; EMR BMI from Arcadia, Veradigm and S42 (~176M lives). Patients deduplicated across sources; time window to confirm. Identification, not treatment eligibility. Uplift may vary by specific use case.*

*\*\*\* HealthVerity Source 98, de-identified card transactions linked at the patient level; 35 tracked GLP-1 and telehealth merchants, Jul 2025–Jun 2026. Patients may use more than one merchant. Merchants blinded. Uplift may vary by specific use case.*

[View full post](https://blog.healthverity.com/why-brand-teams-miss-commercial-growth-and-what-the-data-reveals)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "HealthVerity"
  },
  "dateModified" : "2026-11-19T09:00:00.518Z",
  "datePublished" : "2026-11-19T09:00:00Z",
  "headline" : "Why brand teams miss commercial growth (and what the data reveals)",
  "image" : {
    "@type" : "ImageObject",
    "height" : 628,
    "url" : "https://info.healthverity.com/hubfs/why-brand-teams-miss-commercial-growth-featured.png",
    "width" : 1200
  },
  "mainEntityOfPage" : "https://blog.healthverity.com/why-brand-teams-miss-commercial-growth-and-what-the-data-reveals",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "HealthVerity Blog"
  }
}
```